Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial
Event:
ESC Congress 2016
Topic:
Atrial fibrillation (AF)
Session:
Anticoagulation in atrial fibrillation III
